1,477 reports of this reaction
3.0% of all DOXAZOSIN reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for DOXAZOSIN, manufactured by ROERIG. There are 1,477 FDA adverse event reports linking DOXAZOSIN to DYSPNOEA. This represents approximately 3.0% of all 48,526 adverse event reports for this drug.
DOXAZOSIN has an overall safety score of 85 out of 100. Patients taking DOXAZOSIN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for DOXAZOSIN, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for DOXAZOSIN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,477 FDA reports for DOXAZOSIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.0% of all adverse event reports for DOXAZOSIN, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking DOXAZOSIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.